These data suggest that APX3330 treatment could clinically benefit normal individuals carrying TET2 mutations that show signs of clonal hematopoiesis, as well as patients with TET2 mutations who have AML, myeloproliferative disease and myelodysplastic syndrome. The gene discussed is TET2; the disease is acute myeloid leukemia.